DarÉ Bioscience 宣布，其针对持续性高危HPV感染的潜在疗法Dare-HPV的二期临床试验新药申请已获得美国食品药品监督管理局（FDA）批准。持续性高危HPV感染是导致宫颈癌的最主要病因。
DarÉ Bioscience 宣布，其针对持续性高危HPV感染的潜在疗法Dare-HPV的二期临床试验新药申请已获得美国食品药品监督管理局（FDA）批准。持续性高危HPV感染是导致宫颈癌的最主要病因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.